Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARTELO BIOSCIENCES, INC.ARTL · Entity 8413 | Director | July 17, 2026 | July 21, 2026 |
| TuHURA Biosciences, Inc./NVKTRA · Entity 6601 | Director | August 30, 2023 | September 01, 2023 |
| Viridian Therapeutics, Inc.\DESGNL · Entity 4316 | CFO, Secretary, Treasurer | October 31, 2016 | November 03, 2016 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | June 04, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARTELO BIOSCIENCES, INC.
Report date July 17, 2026 · Filed July 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2036-07-17 | Direct | 136 |
Reported balance
After 2026-07-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-17 · Grant · Acquired 136 · Balance 136 F1: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.
TuHURA Biosciences, Inc./NV
Report date August 30, 2023 · Filed September 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.66 · Expires 2033-08-30 | Direct | 8,500 |
Reported balance
After 2023-08-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-30 · Grant · Acquired 8,500 · Balance 8,500 F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023.
Viridian Therapeutics, Inc.\DE
Report date October 31, 2016 · Filed November 03, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 72,994 |
Reported balance
After 2016-10-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-10-31 · Exercise / conversion · Acquired 46,000 · Balance 72,994 F1: Restricted stock units converted into common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 52,027 |
Reported balance
After 2016-10-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2016-10-31 · Tax withholding · Disposed 20,967 · Balance 52,027 F2: Shares withheld to satisfy tax withholding obligations. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 152,027 |
Reported balance
After 2016-10-31 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2016-10-31 · Exercise / conversion · Acquired 100,000 · Balance 152,027 F1: Restricted stock units converted into common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 106,447 |
Reported balance
After 2016-10-31 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2016-10-31 · Tax withholding · Disposed 45,580 · Balance 106,447 F2: Shares withheld to satisfy tax withholding obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-10-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-10-31 · Exercise / conversion · Disposed 46,000 · Balance 0 F1: Restricted stock units converted into common stock on a one-for-one basis. F3: On August 4, 2014, the reporting person was granted 92,000 restricted stock units. In connection with the execution of the Agreement and Plan of Merger and Reorganization, dated October 31, 2016, by and among Signal Genetics, Inc. (the "Issuer"), Signal Merger Sub, Inc. and Miragen Therapeutics, Inc. (the "Merger Agreement"), the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of the remaining 46,000 restricted stock units in full. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-10-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-10-31 · Exercise / conversion · Disposed 100,000 · Balance 0 F1: Restricted stock units converted into common stock on a one-for-one basis. F4: On March 28, 2016, the reporting person was granted 100,000 restricted stock units. In connection with the execution of the Merger Agreement, the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of these restricted stock units in full. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units converted into common stock on a one-for-one basis.
F2: Shares withheld to satisfy tax withholding obligations.
F3: On August 4, 2014, the reporting person was granted 92,000 restricted stock units. In connection with the execution of the Agreement and Plan of Merger and Reorganization, dated October 31, 2016, by and among Signal Genetics, Inc. (the "Issuer"), Signal Merger Sub, Inc. and Miragen Therapeutics, Inc. (the "Merger Agreement"), the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of the remaining 46,000 restricted stock units in full.
F4: On March 28, 2016, the reporting person was granted 100,000 restricted stock units. In connection with the execution of the Merger Agreement, the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of these restricted stock units in full.
ZEVRA THERAPEUTICS, INC.
Report date June 04, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2036-06-03 | Direct | 30,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.
F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 17, 2026 Filed Jul 21, 2026 22:24 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 136 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001640334-26-001221 · form4.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires 2036-07-17 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026. Read SEC document |
| June 04, 2026 Filed Jun 18, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0001434647-26-000055 · wk-form4_1781813796.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-03 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:45 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Options (right to buy) · Derivative | 292 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001640334-26-000195 · form4.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292 Underlying: Common Stock · 292 shares Expires 2036-01-30 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 30, 2026. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 01:28 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $19,793.00 Strike: $3.40 | $19,793.00 |
DisclosureSEC source: 0001640334-25-001923 · form4.xml · derivative · entry 4 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2026-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · derivative.underlying_shares: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · derivative.underlying_shares: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 01:28 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | ConversionWarrant (right to buy) · Derivative | 12,566 | Not disclosed Strike: $3.40 | Not disclosed |
DisclosureSEC source: 0001640334-25-001923 · form4.xml · derivative · entry 3 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,566 Underlying: Common Stock · 12,566 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · price: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · price: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 01:28 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | ConversionWarrant (right to buy) · Derivative | 6,846 | Not disclosed Strike: $6.24 | Not disclosed |
DisclosureSEC source: 0001640334-25-001923 · form4.xml · derivative · entry 2 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,846 Underlying: Common Stock · 6,846 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F2 · price: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · price: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 01:28 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $25,000.00 | $25,000.00 |
DisclosureSEC source: 0001640334-25-001923 · form4.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · derivative.exercise_price: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · derivative.underlying_shares: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · derivative.underlying_shares: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 20:15 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 3,175 | $7.79 | $24,718.01 |
DisclosureSEC source: 0001288232-25-000009 · wk-form4_1758053735.xml · nonDerivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,894 Read SEC document |
| May 29, 2025 Filed May 31, 2025 01:39 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001437749-25-019047 · rdgdoc.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-05-28 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:24 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | PurchaseConvertible Promissory Note · Derivative | Not disclosed | $25,000.00 | $25,000.00 |
DisclosureSEC source: 0001640334-25-000789 · form4.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2025-10-28 F1 · derivative.exercise_price: On or about May 1, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") with the Reporting Person, pursuant to which the Issuer issued a convertible note (the "Note") to the Reporting Person. The Notes will accrue interest at a rate of 12% per annum, which will adjust to 20% upon an Event of Default (as defined in the Note). All unpaid principal, together with any then unpaid and accrued interest and other amounts payable thereunder, shall be due and payable on October 28, 2025 (the "Maturity Date"). F2 · derivative.exercise_price: At the Maturity Date, the Reporting Person may (at the Reporting Person's sole option) convert all of that certain unpaid portion of principal and accrued interest of the Reporting Person's Note into shares of the Issuer's common stock ("Common Stock") (the "Voluntary Conversion"), specifically into that number of shares of Common Stock (the "Converted Shares") equal to the unpaid principal balance and any accrued interest of each Note divided by $1.29. The amount of principal balance and any accrued interest of the Note convertible pursuant to the Voluntary Conversion shall be the number of Converted Shares multiplied by $1.04 (the "Minimum Price"). Should the Reporting Person not elect Voluntary Conversion, such portion of the unpaid principal balance and any accrued interest of the Note subject to Voluntary Conversion shall be immediately due and payable in cash. F3 · derivative.exercise_price: At the Maturity Date, that portion of the unpaid principal balance and any accrued interest of the Note not subject to the Voluntary Conversion shall be automatically converted into a warrant to purchase shares of the Issuer's Common Stock (the "Warrant") at a conversion price of $0.125 per share issuable pursuant to the Warrant (the "Automatic Conversion"). The exercise price of such Warrant for each Warrant Share shall be equal to the Minimum Price. F1 · derivative.underlying_shares: On or about May 1, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") with the Reporting Person, pursuant to which the Issuer issued a convertible note (the "Note") to the Reporting Person. The Notes will accrue interest at a rate of 12% per annum, which will adjust to 20% upon an Event of Default (as defined in the Note). All unpaid principal, together with any then unpaid and accrued interest and other amounts payable thereunder, shall be due and payable on October 28, 2025 (the "Maturity Date"). F2 · derivative.underlying_shares: At the Maturity Date, the Reporting Person may (at the Reporting Person's sole option) convert all of that certain unpaid portion of principal and accrued interest of the Reporting Person's Note into shares of the Issuer's common stock ("Common Stock") (the "Voluntary Conversion"), specifically into that number of shares of Common Stock (the "Converted Shares") equal to the unpaid principal balance and any accrued interest of each Note divided by $1.29. The amount of principal balance and any accrued interest of the Note convertible pursuant to the Voluntary Conversion shall be the number of Converted Shares multiplied by $1.04 (the "Minimum Price"). Should the Reporting Person not elect Voluntary Conversion, such portion of the unpaid principal balance and any accrued interest of the Note subject to Voluntary Conversion shall be immediately due and payable in cash. F3 · derivative.underlying_shares: At the Maturity Date, that portion of the unpaid principal balance and any accrued interest of the Note not subject to the Voluntary Conversion shall be automatically converted into a warrant to purchase shares of the Issuer's Common Stock (the "Warrant") at a conversion price of $0.125 per share issuable pursuant to the Warrant (the "Automatic Conversion"). The exercise price of such Warrant for each Warrant Share shall be equal to the Minimum Price. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 21:00 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,750 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001640334-24-001925 · form4.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires 2034-12-20 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean December 20, 2024. Read SEC document |
| May 13, 2024 Filed May 16, 2024 01:20 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 49,200 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001437749-24-017182 · rdgdoc.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,200 Underlying: Common Stock · 49,200 shares Expires 2034-05-12 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 13, 2024. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:53 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,083 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 10 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,083 Underlying: Common Stock · 1,083 shares Expires 2033-08-04 F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:53 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 9 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2033-06-30 F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:53 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 8 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2032-06-24 F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:53 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 7 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2031-07-16 F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:53 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 2,000 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 6 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2031-03-05 F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:53 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 1,083 | Not disclosed Strike: $2.01 | Not disclosed |
DisclosureSEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 5 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,083 shares Expires 2033-08-04 F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F7 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean August 4, 2023. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:53 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.99 | Not disclosed |
DisclosureSEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 4 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires 2033-06-30 F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F6 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 30, 2023. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:53 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $4.89 | Not disclosed |
DisclosureSEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 3 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires 2032-06-24 F5 · derivative.exercise_price: This option was granted on June 24, 2022 and was previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F5 · derivative.underlying_shares: This option was granted on June 24, 2022 and was previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:53 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 2 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires 2031-07-16 F4 · derivative.exercise_price: This option was granted on July 16, 2021 and was previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F4 · derivative.underlying_shares: This option was granted on July 16, 2021 and was previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:53 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 2,000 | Not disclosed Strike: $22.80 | Not disclosed |
DisclosureSEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2031-03-05 F1 · derivative.exercise_price: This option was granted on March 5, 2021 and was previously reported as covering 30,000 shares at an exercise price of $1.52 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan (the "Plan")) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, one third (1/3rd) of the shares subject to the option shall vest on the two (2) year anniversary of the Vesting Commencement Date, one third (1/3rd) of the shares subject to the option shall vest on the three (3) year anniversary of the Vesting Commencement Date, such that the option shall be fully vested on the three (3) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 5, 2021. F1 · derivative.underlying_shares: This option was granted on March 5, 2021 and was previously reported as covering 30,000 shares at an exercise price of $1.52 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 22:00 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001493152-23-031535 · ownership.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2033-08-30 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:54 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,083 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001640334-23-001482 · form4.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,083 Underlying: Common Stock · 1,083 shares Expires 2033-08-04 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean August 4, 2023. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 18:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001640334-23-001201 · form4.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2033-06-30 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 30, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:33 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001437749-23-016494 · rdgdoc.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-30 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 31, 2023. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 25, 2023 Filed May 9, 2023 01:51 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 39,200 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001437749-23-013124 · rdgdoc.xml · derivative · entry 1 FAVORITO TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,200 Underlying: Common Stock · 39,200 shares Expires 2033-04-24 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's eighth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:32 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 519 | $4.82 | $2,502.36 |
DisclosureSEC source: 0001437749-23-007397 · rdgdoc.xml · nonDerivative · entry 1 SEYMOUR TAMARA A · CIK 0001288232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 719 Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:05 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001493152-22-018529 · ownership.xml · derivative · entry 1 SEYMOUR TAMARA A · CIK 0001288232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-07-01 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on August 1, 2022. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 21:19 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001437749-22-016300 · rdgdoc.xml · derivative · entry 1 SEYMOUR TAMARA A · CIK 0001288232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-27 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 28, 2022. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 21:17 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001640334-22-001357 · form4.xml · derivative · entry 1 SEYMOUR TAMARA A · CIK 0001288232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-24 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 24, 2022. Read SEC document |
| May 20, 2022 Filed May 25, 2022 00:58 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 200 | $4.87 | $974.00 |
DisclosureSEC source: 0001437749-22-013468 · rdgdoc.xml · nonDerivative · entry 1 SEYMOUR TAMARA A · CIK 0001288232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 00:37 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0000905718-21-001223 · kintara_fm4sep222021.xml · derivative · entry 1 SEYMOUR TAMARA A · CIK 0001288232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-09-22 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021. Read SEC document |
| July 16, 2021 Filed Jul 26, 2021 20:22 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001640334-21-001675 · form4.xml · derivative · entry 1 SEYMOUR TAMARA A · CIK 0001288232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-16 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 16, 2021. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:34 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Grant) · Derivative | 75,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0000905718-21-000652 · kintara_fm4apr292021.xml · derivative · entry 1 SEYMOUR TAMARA A · CIK 0001288232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-04-29 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, one-third of the options vest on April 29, 2022, with the remaining options vesting in eight equal quarterly installments commencing on July 29, 2022. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:24 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001640334-21-000542 · form4.xml · derivative · entry 1 SEYMOUR TAMARA A · CIK 0001288232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-03-05 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, one third (1/3rd) of the shares subject to the option shall vest on the two (2) year anniversary of the Vesting Commencement Date, one third (1/3rd) of the shares subject to the option shall vest on the three (3) year anniversary of the Vesting Commencement Date, such that the option shall be fully vested on the three (3) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 5, 2021. Read SEC document |
| October 31, 2016 Filed Nov 3, 2016 00:39 UTC | Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 | Exercise / conversionRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-148045 · doc4.xml · derivative · entry 6 SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis. F4 · derivative.exercise_date: On March 28, 2016, the reporting person was granted 100,000 restricted stock units. In connection with the execution of the Merger Agreement, the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of these restricted stock units in full. F4 · derivative.expiration_date: On March 28, 2016, the reporting person was granted 100,000 restricted stock units. In connection with the execution of the Merger Agreement, the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of these restricted stock units in full. Read SEC document |
| October 31, 2016 Filed Nov 3, 2016 00:39 UTC | Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 | Exercise / conversionRestricted Stock Units · Derivative | 46,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-148045 · doc4.xml · derivative · entry 5 SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: On August 4, 2014, the reporting person was granted 92,000 restricted stock units. In connection with the execution of the Agreement and Plan of Merger and Reorganization, dated October 31, 2016, by and among Signal Genetics, Inc. (the "Issuer"), Signal Merger Sub, Inc. and Miragen Therapeutics, Inc. (the "Merger Agreement"), the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of the remaining 46,000 restricted stock units in full. F3 · derivative.expiration_date: On August 4, 2014, the reporting person was granted 92,000 restricted stock units. In connection with the execution of the Agreement and Plan of Merger and Reorganization, dated October 31, 2016, by and among Signal Genetics, Inc. (the "Issuer"), Signal Merger Sub, Inc. and Miragen Therapeutics, Inc. (the "Merger Agreement"), the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of the remaining 46,000 restricted stock units in full. Read SEC document |
| October 31, 2016 Filed Nov 3, 2016 00:39 UTC | Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 | Tax withholdingCommon Stock | 45,580 | $0.36 | $16,408.80 |
DisclosureSEC source: 0001209191-16-148045 · doc4.xml · nonDerivative · entry 4 SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 106,447 F2 · shares: Shares withheld to satisfy tax withholding obligations. Read SEC document |
| October 31, 2016 Filed Nov 3, 2016 00:39 UTC | Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 | Exercise / conversionCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-148045 · doc4.xml · nonDerivative · entry 3 SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 152,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis. Read SEC document |
| October 31, 2016 Filed Nov 3, 2016 00:39 UTC | Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 | Tax withholdingCommon Stock | 20,967 | $0.36 | $7,548.12 |
DisclosureSEC source: 0001209191-16-148045 · doc4.xml · nonDerivative · entry 2 SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 52,027 F2 · shares: Shares withheld to satisfy tax withholding obligations. Read SEC document |
| October 31, 2016 Filed Nov 3, 2016 00:39 UTC | Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 | Exercise / conversionCommon Stock | 46,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-148045 · doc4.xml · nonDerivative · entry 1 SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 72,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.